New York, NY -- (SBWIRE) -- 01/28/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Horizon Pharma Inc (NASDAQ:HZNP), Monster Worldwide, Inc (NYSE:MWW), Zalicus Inc (NASDAQ:ZLCS), BioScrip Inc (NASDAQ: BioScrip Inc (NASDAQ:BIOS)
Horizon Pharma Inc (NASDAQ:HZNP) showed a volume of 1.73 million shares by the end of last trade whereas the average volume of the stock remained 1.59 million shares. The stock opened the session at $8.34 but then moved to $7.93. At that price, the stock showed a negative performance of -4.80%. Horizon Pharma, Inc. operates as a biopharmaceutical company. It is focused on developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.
Will HZNP Get Buyers Even After The Recent Rally? Find Out Here
Monster Worldwide, Inc (NYSE:MWW) opened the session at $6.10 and closed the session at $6.20. The stock showed a positive performance of 1.64% in previous trading session. Traded with volume of 1.72 million shares in the prior session and the average volume of the stock remained 2.17 million shares. Monster Worldwide, Inc. (Monster Worldwide) is parent company of Monster, the global online employment solution. With a presence in approximately 55 countries globally, including key markets in North America, Europe, South America and the Asia-Pacific region,
For How Long MWW will fight for Profitability? Read This Trend Analysis report
Zalicus Inc (NASDAQ:ZLCS) opened the session at $1.66 and closed the session at $1.50. The stock showed a negative performance of -8.54% in previous trading session. Traded with volume of 1.64 million shares in the prior session and the average volume of the stock remained 1.79 million shares. Zalicus Inc. (Zalicus) is a biopharmaceutical company that discovers and developsl treatments for patients suffering from pain and immuno-inflammatory diseases.
Why Should Investors Buy ZLCS After the Recent Fall? Just Go Here and Find Out
BioScrip Inc (NASDAQ: BioScrip Inc (NASDAQ:BIOS) the stock decreased -1.93% and finished the session at $8.11. Traded with volume of 1.63 million shares in the prior session and the average volume of the stock remained 1.35 million shares. The beta of the stock remained 1.45. BioScrip, Inc. (BioScrip) is a provider of pharmacy and home health services, which partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and the delivery of prescription medications and home health services.
Will BIOS Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)